The identification of highly potent novel non-CDN STING ligands which can easily enter into cells without the need of dedicated transporter molecules is a major step forward towards clinical application of STING ligands for instance as adjuvants in tumor immunotherapy19,20,22,33 or as anti-infective therapeutics in viral infections including Sars-CoV-223,24,34,35. This evidence concerns the gene STING1 and neoplasm.